文献速递皮肤感染

早期皮肤莱姆疏螺旋体病的抗生素治疗疗效与安全性:一项网络Meta分析

Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2018-01-01

该网络Meta分析纳入19项随机临床试验共2532例早期皮肤莱姆疏螺旋体病成人患者,比较多种抗生素药物、剂量和疗程的疗效与安全性。汇总效应量未提示不同抗生素药物、剂量或疗程在治疗反应上存在显著差异,治疗失败率在治疗后2个月为4%(95%CI 2%-5%)、12个月为2%(95%CI 1%-3%),治疗相关不良事件在各药物和治疗方式间也无差异,证据确定性多为低和极低。

要点

  • 不同抗生素药物治疗早期皮肤莱姆疏螺旋体病的疗效无显著差异。
  • 不同剂量或疗程的治疗反应无显著差异。
  • 治疗失败率低,2个月为4%(95%CI 2%-5%),12个月为2%(95%CI 1%-3%)。

核心结论

  • 该网络Meta分析提示,抗生素药物或治疗方式均未对比较疗效或药物相关不良结局产生影响。
  • 该发现对治疗莱姆疏螺旋体病患者的医生和患者决策具有相关性。

研究设计与样本

  • 研究为网络Meta分析,纳入关于早期皮肤莱姆疏螺旋体病各种抗生素药物和治疗方式的全部随机临床试验。
  • 检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials,从建库至2017年7月。
  • 共纳入19项研究、2532例患者,患者平均年龄范围37至56岁,女性患者比例范围36%至60%。
  • 纳入标准为经医生确认的早期局限性皮肤感染的成人,接受任何剂量或疗程的抗生素治疗。

主要发现

  • 网络Meta分析的汇总效应量未提示不同抗生素药物在治疗反应上存在显著差异(例如阿莫西林 vs 多西环素,比值比1.26;95%CI 0.41-3.87)。
  • 不同剂量或疗程在治疗反应上无显著差异(例如多西环素200 mg/d用3周 vs 多西环素200 mg/d用2周,比值比1.28;95%CI 0.49-3.34)。
  • 治疗失败在治疗后2个月(4%;95%CI 2%-5%)和12个月(2%;95%CI 1%-3%)均罕见。
  • 不同抗生素药物和治疗方式在治疗相关不良结局的效应量上也无差异,不良事件通常为轻至中度。
  • 证据确定性被归类为低和极低,主要由于纳入研究的不精确性、间接性和研究局限性(高偏倚风险)。

关键数值与推荐

  • 主要结局为治疗反应(症状消退)和治疗相关不良事件。
  • 研究涉及的抗生素包括多西环素、头孢呋辛酯、头孢曲松、阿莫西林、阿奇霉素、青霉素V和米诺环素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据确定性被归类为低和极低,主要由于不精确性、间接性和纳入研究的局限性(高偏倚风险)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Controversies about the choice of antibiotic agent and treatment modality exist in the management of erythema migrans in early cutaneous Lyme borreliosis (LB). OBJECTIVE: To conduct a network meta-analysis (NMA) of all randomized clinical trials on various antibiotic agents and treatment modalities in early cutaneous LB. DATA SOURCES: Electronic searches in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were conducted from inception until July 2017. The reference lists of the included studies were hand searched, authors were contacted, and ongoing trials were searched at ClinicalTrials.gov. STUDY SELECTION: One reviewer screened the titles and abstracts of the 9975 reports identified by the electronic searches. Full-text copies of 161 potentially relevant articles were obtained, and 2 reviewers independently assessed those articles for inclusion. Adults with a physician-confirmed early localized skin infection who were treated with antibiotics of any dose or duration were included. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data on study, patient, and intervention characteristics. Network meta-analyses on treatment effects and adverse outcomes were calculated with a frequentist approach using the R package netmeta. The Grading of Recommendations Assessment, Development and Evaluation guidance for NMA was used to assess the certainty of evidence. MAIN OUTCOMES AND MEASURES: Treatment effects for response to treatment (resolution of symptoms) and treatment-related adverse events. RESULTS: Overall, 19 studies (2532 patients) were included. The mean patient age ranged between 37 and 56 years, and the percentage of female patients ranged from 36% to 60%. The antibiotics investigated were doxycycline, cefuroxime axetil, ceftriaxone, amoxicillin, azithromycin, penicillin V, and minocycline. Pooled effect sizes from NMAs did not suggest any significant differences in treatment response by antibiotic agent (eg, amoxicillin vs doxycycline odds ratio, 1.26; 95% CI, 0.41-3.87), dose, or duration (eg, doxycycline, 200 mg/d for 3 weeks, vs doxycycline, 200 mg/d for 2 weeks, odds ratio, 1.28; 95% CI, 0.49-3.34). Treatment failures were rare at both 2 months (4%; 95% CI, 2%-5%) and 12 months (2%, 95% CI, 1%-3%) after treatment initiation. There were also no differences in the effect sizes among antibiotic agents and treatment modalities for treatment-related adverse outcomes, which were generally mild to moderate. Certainty of evidence was categorized as low and very low mostly because of imprecision, indirectness, and study limitations (high risk of bias) of the included studies. CONCLUSIONS AND RELEVANCE: This NMA suggests that neither the antibiotic agent nor treatment modality contributed to comparative effectiveness or drug-related adverse outcomes. This finding is relevant for physicians treating patients with LB and for patient decision making.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Torbahn G, Hofmann H, Rücker G, et al. Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis. JAMA Dermatol. 2018. PMID: 30285069. doi:10.1001/jamadermatol.2018.3186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。